Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
Nauck MA, Ratner RE, Kapitza C, Berria R, Boldrin M, Balena R. Nauck MA, et al. Among authors: boldrin m. Diabetes Care. 2009 Jul;32(7):1237-43. doi: 10.2337/dc08-1961. Epub 2009 Apr 14. Diabetes Care. 2009. PMID: 19366970 Free PMC article. Clinical Trial.
Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
Raz I, Fonseca V, Kipnes M, Durrwell L, Hoekstra J, Boldrin M, Balena R. Raz I, et al. Among authors: boldrin m. Diabetes Care. 2012 Mar;35(3):485-7. doi: 10.2337/dc11-1942. Epub 2012 Feb 1. Diabetes Care. 2012. PMID: 22301126 Free PMC article. Clinical Trial.
Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
Pratley RE, Urosevic D, Boldrin M, Balena R; T-emerge 6 Study Group. Pratley RE, et al. Among authors: boldrin m. Diabetes Obes Metab. 2013 Mar;15(3):234-40. doi: 10.1111/dom.12009. Epub 2012 Sep 30. Diabetes Obes Metab. 2013. PMID: 22958426 Clinical Trial.
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Gastaldelli A, Balas B, Ratner R, Rosenstock J, Charbonnel B, Bolli GB, Boldrin M, Balena R. Gastaldelli A, et al. Among authors: boldrin m. Diabetes Obes Metab. 2014 Feb;16(2):170-8. doi: 10.1111/dom.12192. Epub 2013 Aug 22. Diabetes Obes Metab. 2014. PMID: 23911196 Clinical Trial.
44 results